Asthma: Reversible Obstructive Airways Disease (ROAD): SERETIDE is indicated in the regular treatment of ROAD, including asthma in children and adults, where the use of a combination (bronchodilator and inhaled corticosteroid) is appropriate.
This may include: Patients on effective maintenance doses of long-acting beta-agonists and inhaled corticosteroids.
Patients who are symptomatic on current inhaled corticosteroid therapy.
Patients on regular bronchodilator therapy who require inhaled corticosteroids.
Chronic Obstructive Pulmonary Disease (COPD): SERETIDE is indicated for the Regular treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.
Patients should be given the strength of SERETIDE containing the appropriate fluticasone propionate dosage for the severity of their disease.
Two inhalations of 25 micrograms salmeterol and 125 micrograms fluticasone propionate twice daily. or;
Two inhalations of 25 micrograms salmeterol and 250 micrograms fluticasone twice daily.
Children 4 years and older: Two inhalations of 25 micrograms salmeterol and 50 micrograms fluticasone propionate twice daily.
There are no data available for use of SERETIDE in children aged under 4 years.
Chronic Obstructive Pulmonary Disease (COPD): For adult patients the recommended dose is two inhalations 25/125 micrograms to 25/250 micrograms salmeterol/fluticasone propionate twice daily.